Articles from LEO Pharma Inc.

LEO Pharma Inc. announced today that the Food and Drug Administration (FDA) has approved ANZUPGO® (delgocitinib) cream for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.5

Sixty-five percent of dermatology providers surveyed agree there is a lack of education and understanding of chronic hand eczema (CHE) as a condition separate from atopic dermatitis (AD), according to the first phase of the survey commissioned by LEO Pharma Inc., a global leader in medical dermatology, and conducted by Ipsos.

LEO Pharma Inc., a global leader in medical dermatology, today presented the final results of the five-year extension study ECZTEND, showing the long-term safety and efficacy profile of Adbry® (tralokinumab-ldrm) in adults and adolescent patients (aged 12 years and over) with moderate-to-severe atopic dermatitis (AD).1 The findings were presented in a poster at the Fall Clinical Dermatology Conference in Las Vegas, Nevada, from October 24-27, 2024.

LEO Pharma Inc., a global leader in medical dermatology, will present a comprehensive catalog of new data around investigational delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE) and Adbry® (tralokinumab-ldrm) in the treatment of patients 12 years of age or older with moderate to severe atopic dermatitis (AD). The findings are being presented across 18 posters at the 2024 Fall Clinical Dermatology Conference taking place from Oct. 24-27 in Las Vegas, Nevada.

LEO Pharma Inc., a global leader in medical dermatology, has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE) – a debilitating skin condition for which there are currently no FDA approved treatments.1

LEO Pharma Inc. announced today the availability of the Adbry® (tralokinumab-ldrm) 300 mg/2 mL single-dose autoinjector in the United States. Adbry is currently indicated in the U.S. for patients 12 years and older with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.1

NOT FOR UK USE – NOT INTENDED FOR UK MEDIA

LEO Pharma Inc, a global leader in medical dermatology, today announced that the British Journal of Dermatology published detailed results from a pooled safety analysis of Adbry™ (tralokinumab-ldrm) from three pivotal Phase 3 trials (ECZTRA 1, 2, and ECZTRA 3), Phase 2 (ECZTRA 5) and Phase 2b trials of adult patients with moderate-to-severe atopic dermatitis (AD). The analysis evaluated the safety profile of Adbry compared to placebo over the initial 16-week treatment period and up to 52 weeks, as measured by the overall frequency and severity of adverse events (AEs).1 Initial study results were presented online at EADV Virtual 2020.2

LEO Pharma Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Adbry™ (tralokinumab-ldrm) for the treatment of moderate-to-severe atopic dermatitis in adults 18 years or older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids.1 Adbry is the first and only FDA approved biologic that specifically binds to and inhibits the IL-13 cytokine, a key driver of atopic dermatitis signs and symptoms.1,3,4